The Executive group of the international clinical research decided to resume testing of hydroxychloroquine for the treatment of patients with coronavirus infection. This was at the briefing on 3 June, said General Director of the world health organization tedros adhanom Ghebreyesus, informs the press service of the who.
He recalled that in late may, drug testing suspended to evaluate potential risks.
“Based on available data about mortality of the members of the Committee for security and monitoring data concluded that there is no reason to change the treatment Protocol. The Executive team had received the recommendation and approved the continuation of all clinical trials, including hydroxychloroquine,” he said Ghebreyesus.
The program, initiated by the who after the start of the pandemic COVID-19, attended by more than 3,500 patients from 35 countries.
Hydroxychloroquine used in malaria, lupus, rheumatoid arthritis, tested in some countries for the treatment of coronavirus infection. Some researchers have pointed to its effectiveness, but, according to others, it can cause serious adverse reactions, including disruption of the cardiovascular system. The American Management on sanitary inspection behind quality of foodstuff and medicines has warned against the use of hydroxychloroquine for the treatment of coronavirus infection outside medical institutions because of risk of irregular heart rhythm.
The President of the United States Donald trump within two weeks of taking hydroxychloroquine for the prevention of coronavirus disease.
Hydroxychloroquine in the treatment of COVID-19 is used in Ukraine, reported the Ministry of health.
Special medications from coronavirus infection COVID-19 until there is only symptomatic treatment.